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Abstract: Inﬂ  ammatory bowel disease (IBD) is characterized by inﬂ  ammation of the gastroin-
testinal tract, typically with a relapsing and remitting clinical course. The intestinal inﬂ  ammation 
in IBD is controlled by a complex interplay of innate and adaptive immune mechanisms. Innate 
immunity comprises a set of distinct elements, which includes circulating cells such as neutro-
phils, monocytes, and resident intestinal immune cells (dendritic and Paneth cells), as well as 
intestinal epithelium and cellular products, including antimicrobial peptides such as defensins 
and cathelicidins. Different components of innate immunity in IBD have been suggested to be 
defective or impaired. The human granulocyte-macrophage colony-stimulating factor (GM-CSF) 
and the human granulocyte colony-stimulating factor (G-CSF) have emerged as potential tools 
for the modulation of intestinal inﬂ  ammation and repair. The greatest evidence supporting the 
use of colony-stimulating factors in intestinal inﬂ  ammation comes from studies conducted in 
active Crohn’s disease (CD) patients treated with sargramostim and ﬁ  lgrastim, but evidence 
for its recommendation as treatment remains weak, as the majority of studies are open label, 
nonrandomized, and with a small number of patients.
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Introduction
Inﬂ  ammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative 
colitis (UC), represents a group of chronic disorders characterized by inﬂ  ammation 
of the gastrointestinal tract, typically with a relapsing and remitting clinical course. 
Mucosal macrophages play an important role in the mucosal immune system, and 
an increase in the number of newly recruited monocytes and activated macrophages 
has been noted in the inﬂ  amed gut of patients with IBD. Activated macrophages are 
thought to be major producers of inﬂ  ammatory cytokines in the gut, and imbalance 
of cytokines contributes to the pathogenesis of IBD. The intestinal inﬂ  ammation in 
IBD is controlled by a complex interplay of innate and adaptive immune mechanisms, 
where colony-stimulating factors (CSF) may have a potential therapeutic role that 
remains to be strongly proved.
The potential usefulness of CSF in IBD emerged from the knowledge of the 
underlying immunological disorders in genetic diseases associated with CD or with 
a Crohn’s-like intestinal disease, such as chronic granulomatous disease (Myrup et al 
1998), glycogen storage disease Ib (Roe et al 1992), and cyclic neutropenia (Fata et al 
1997), among others, where CSF had been shown to be useful. At this time, there is 
evidence that CSF may be an alternative treatment for IBD, but evidence is still insuf-
ﬁ  cient to recommend it in clinical practice.
Innate immunity in IBD
Innate immunity comprises a set of distinct elements, which includes circulating cells 
such as neutrophils, monocytes, and resident intestinal immune cells (dendritic and Biologics: Targets & Therapy 2008:2(3) 502
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Paneth cells) as well as intestinal epithelium and cellular 
products (defensins and cathelicidins). Different components 
of innate immunity in IBD have been suggested to be defec-
tive or impaired (Yamamoto-Furusho and Korzenik 2006), 
and there remain the potential therapeutic effects of CSF.
Below we describe the sites where CSF may act in the 
pathogenesis of IBD related to immune defects.
Neutrophil defects and impaired
mucosal innate immune response
Several defects have been described in patients with CD, 
including impairment in migration of neutrophils (Segal et al 
1976); complement dysfunction that produces impair neutro-
phil recruitment (Elmgreen 1986); decreased phagocytic and 
bactericidal neutrophil functions (Wandall 1985); and deﬁ  cient 
superoxide generation in neutrophils (Curran et al 1991).
A signiﬁ  cantly diminished production of IL-8 and IL-1β
(45% and 50% reduction, respectively) was found from 
macrophages of patients with CD (Marks et al 2006). Despite 
previous emphasis on adaptive immune dysfunction, there is 
evidence that patients with CD possess a weak acute innate 
inﬂ  ammatory response (Rahman et al 2008). This failure 
of inﬂ  ammatory mediator production leads to insufﬁ  cient 
recruitment of neutrophils, resulting in inadequate removal of 
bacteria and other debris (Marks and Segal 2008), perpetuat-
ing the aberrant inﬂ  ammatory response. The increased tissue 
migration of neutrophils with CSF therapy may explain its 
potential beneﬁ  ts in CD (Harbord et al 2006).
Effect of NOD2 mutations
NOD2 is a cytoplasmic protein that serves as a microbial 
sensor, and its leucine-rich repeat (LRR) domain is required 
for recognition of muramyl dipeptide (MDP), a fragment 
of peptidoglycan present in bacterial cell walls. Membrane 
recruitment of NOD2 is essential for NF-kB activation after 
the recognition of MDP and exerts antibacterial activity in 
intestinal epithelial cells.
Specific mutations of the NOD2 gene (Arg702Trp, 
Gly908Arg, and leu1007fsinsC) produce selective functional 
defects in leukocytes of patients with CD as shown by van Heel 
et al (2005) who analyzed cytokine expression of peripheral 
blood mononuclear cells after exposure to muramyl dipeptide 
(MDP). In PBMC from CD patients the NOD2 ligand induced 
little TNFα and IL-1β, but strong IL-8 secretion. Furthermore, 
monocytes isolated from CD patients carrying the 1007fs 
(3020insC) mutation were reported to exhibit defects in the 
production of the proinﬂ  ammatory cytokines, TNFα, IL-6 
and IL-8, as well as the anti-inﬂ  ammatory cytokine IL-10 
(Netea et al 2005). These ﬁ  ndings were recently conﬁ  rmed by 
Beynon et al (2008), who also found an impaired release of 
IL-12p40, which may be a new link between NOD2 mutations 
and the inﬂ  ammatory mechanisms. Dendritic cells derived 
from CD patients homozygous for leu1007fsinsC also fail to 
up-regulate the costimulatory molecules CD80 and CD86 in 
response to MDP and lack production of cytokines such as 
TNF-α, IL-12, and IL-10 (Kramer et al 2006).
In general, α-defensins (1–3, 5, and 6) production by 
Paneth cells is diminished in the colonic mucosa of CD and UC 
patients. NOD2 mutations in CD patients have been associated 
with diminished mucosal α-defensin expression (Wehkamp 
et al 2004), but recently it was found that this reduction could 
be independent (Simms et al 2008). Decreased β-defensin 1 
and the lack of induction of inducible antimicrobial peptides 
β-defensins 2 and 3 in CD could result in enhanced bacterial 
survival and perhaps invasion (Fellermann et al 2003), 
probably leading to activation of the previously explained 
impaired immune response and triggering IBD.
Experimental and preclinical
studies
The human granulocyte-macrophage colony-stimulating 
factor (GM-CSF) was shown to be clinically and histologically 
effective in dextran sulfate sodium-induced acute colitis 
model in mice (Sainathan et al 2008).
Immune complex colitis was induced in White New 
Zealand rabbits to evaluate the effect of the human granu-
locyte colony-stimulating factor G-CSF 50–200 μg/kg on 
colonic mucosal inﬂ  ammation, neutrophil recruitment, and 
the generation of eicosanoids. It was found that therapy with 
G-CSF resulted in a marked decrease of proinﬂ  ammatory 
mediators, but mucosal generation of the protective prosta-
glandin E2 was preserved, suggesting that it may have anti-
inﬂ  ammatory effects in colitis (Hommes et al 1996). G-CSF 
also showed an effect on preventing the onset of Th1-type 
2,3,6-trinitrobenzene sulfonic acid-induced (TNBS) colitis 
in mice (Yoshimitsu et al 2006).
Polymorphonuclear neutrophils apoptosis in tissues of 
colonic mucosa of UC and CD patients may be delayed under 
the inﬂ  uence of G-CSF (Kenji et al 1999). Furthermore, G-CSF 
therapy increases neutrophil tissue migration in CD, which may 
be involved in its therapeutic effect (Harbord et al 2006).
Options for colony-stimulating 
factors
Growth factors have recently emerged as potential tools 
for the modulation of intestinal inﬂ  ammation and repair. Biologics: Targets & Therapy 2008:2(3) 503
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These factors play an important role in the modulation of 
cellular proliferation, differentiation, angiogenesis, and 
inﬂ  ammation. At least 30 different growth factors are relevant 
for the maintenance of gut mucosal integrity, including 
GM-CSF and G-CSF. The greatest evidence supporting the 
use of colony-stimulating factors in intestinal inﬂ  ammation 
comes from studies conducted in patients with active 
CD: sargramostim and ﬁ  lgrastim.
GM-CSF
Initial findings suggested that patients treated with 
sargramostim (GM-CSF) (Immunex Corporation, Seattle, 
WA, USA) in active CD had a high rate of clinical response 
and remission, with limited side effects (Dieckgraefe and 
Korzenik 2002). This 8-week, open-label, dose-escalating 
study, was conduced on 15 patients with Crohn’s Disease 
Activity Index (CDAI; Best et al 1976) greater than 220 
but lower than 475. Among them, 80% achieved clinical 
response (decrease in CDAI   70 points) and 53% achieved 
remission (CDAI   150). The response rate was 75%, 85%, 
and 75% in the 4, 6, and 8 μg/kg/day dose groups. The only 
patient with a ﬁ  stula had complete clinical closure of a 
chronic rectovaginal ﬁ  stula. Treatment with sargramostim 
also improved quality of life.
Lastly, the Sargramostim in Crohn’s Disease Study Group 
(Korzenik et al 2005) conducted a multicenter, random-
ized, placebo-controlled trial, which included 124 patients. 
Patients were randomly assigned in a 2:1 ratio to receive 
sargramostim (6 μg/kg body weight) or placebo subcutane-
ously daily for 56 days. The primary end-point was clinical 
response and other end-points included changes in disease 
severity, quality of life, and adverse events. Of the 81 patients 
in the sargramostim group, 57 (86%) completed treatment, 
and of the 43 of the placebo group, 37 (86%) completed 
treatment.
The primary end-point was not proven; this was achieved 
in 54% in the sargramostim group and 44% in the placebo 
group (p = 0.28), but a clinical response deﬁ  ned by a decrease 
from baseline of at least 100 points in the CDAI score was 
signiﬁ  cantly higher in the sargramostim group than in the pla-
cebo group (48% vs 26%, p = 0.01), as well as the remission 
rate (40% vs 19%, p = 0.01). The improvement, including 
remission rates, was also superior in the sargramostim group 
30 days after treatment. In patients in whom the validated 
Crohn’s Disease Endoscopic Index of Severity was assessed, 
the median post-treatment scores were signiﬁ  cantly lower in 
the sargramostim group, but the median decrease between 
the two groups was not. Draining ﬁ  stulae was eliminated in 
4 of 8 of patients in the treatment group and in 2 of 5 in the 
placebo group. Only 1 of 78 patients had detectable neutral-
izing antibodies at day 57, and no association was observed 
with adverse events.
Treatment with GM-CSF may provide effective syner-
gistic or single-agent treatment alternatives to immunosup-
pression for IBD (Dieckgraefe et al 2006), but evidence that 
supports its recommendation as treatment remains weak.
G-CSF
Dejaco et al (2003) performed an open-label pilot study with 
ﬁ  lgrastim (Neupogen®, Amgen Inc, Thousand Oaks, CA, 
USA) in 5 CD patients with severe endoscopic postoperative 
recurrence, but with clinically inactive CD (CDAI < 150). 
Patients received 300 μg of ﬁ  lgrastim subcutaneously, 3 times 
weekly for a total of 12 weeks, for the primary objective 
of evaluating safety and efﬁ  cacy in this group of patients. 
Efﬁ  cacy was evaluated by ileocolonoscopy, including his-
topathological examination according to Rutgeerts’ rating 
for postoperative recurrence (Rutgeerts et al 1990), which 
was performed before treatment and within 1 week after 
the end of treatment. Four patients had stricturing and 1 had 
penetrating behavior. Complete mucosal healing occurred in 
2 patients after treatment (1 patient after 12 weeks of therapy 
and in 1 patient 9 months after treatment cessation), and all 
other patients had no response. In 1 patient closure of peri-
anal ﬁ  stulas was noted. This study suggested that despite the 
small number of patients, ﬁ  lgrastim seems to be safe, well 
tolerated, and might provide efﬁ  cacy in CD.
Korzenik and Dieckgraefe (2005) conducted a 12-week 
open-label trial with ﬁ  lgrastim (Neupogen®, Amgen Inc, 
Thousand Oaks, CA, USA) that offered preliminary evidence 
that it is a safe and potentially effective therapy for the 
treatment of active CD and ﬁ  stulous complications. Twenty 
CD patients with a CDAI   220 and   450 were enrolled. 
Primary end-point was a decrease in the CDAI of   70 
points and remission was considered to be a CDAI   150 
points. All patients received ﬁ  lgrastim daily for 12 weeks at 
an initial dose of 300 μg subcutaneously. The absolute neu-
trophil count (ANC) was monitored weekly and was targeted 
between 25 and 35 × 109. The dose was adjusted downward 
by 100 μg if ANC exceeded this range, and after a subsequent 
reduction to 100 μg/day, the dose was lowered to 75 μg/day. 
Five patients (25%) achieved remission during the study, 
11 (55%) demonstrated a decrease of at least 70 points, and 
3 of 4 (75%) patients with ﬁ  stulae had a positive response 
(deﬁ  ned as closure of more than 50% of ﬁ  stulae). Among 
responders at week 12, 4 of 11 patients (36%) maintained Biologics: Targets & Therapy 2008:2(3) 504
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response for additional 4 weeks after completion of therapy 
and the others had an increase in disease activity.
Conclusions
Cellular or animal models, and in vivo experiments support 
the hypothesis that CD may result from innate immune deﬁ  -
ciency characterized by an aberrant innate immune response 
occurring more proximately, leading to T cell activation. 
Several lines of evidence such as functional implications of 
NOD2 mutations, and observations of CD-like manifesta-
tions, have converged to present a coherent hypothesis that 
impaired innate immunity initiates the cascade of events 
resulting in CD. GM-CSF, a more potent stimulator of innate 
immune function than G-CSF, seems to have a beneﬁ  cial 
effect in patients with active CD. Finally, as the majority 
of studies are open label, nonrandomized, and with a small 
number of patients, there is no strong evidence of the effect 
of GM-CSF and G-CSF as treatment for IBD, so evidence 
to supports its recommendation as a treatment is still weak.
Acknowledgments
We thank to Dr. Jorge Hernández-Calleros for the language 
revision of this manuscript.
This work was supported by the scholarship provided by 
the “Secretaria de Relaciones Exteriores” of the Government 
of Mexico.
Disclosures
The authors have no conﬂ  icts of interest to disclose.
References
Best WR, Becktel JM, Singleton JW, et al. 1976. Development of a Crohn’s 
disease activity index. Gastroenterology, 70:439–44.
Beynon V, Cotofana S, Brand S, et al. 2008. NOD2/CARD15 genotype 
inﬂ  uences MDP-induced cytokine release and basal IL-12p40 levels 
in primary isolated peripheral blood monocytes. Inﬂ  amm Bowel Dis. 
DOI: 10.1002/ibd.20441.
Curran FT, Allan RN, Keighley MR. 1991. Superoxide production by 
Crohn’s disease neutrophils. Gut, 32: 399–402.
Dejaco C, Lichtenberger C, Miehsler W, et al. 2003. An open-label pilot study 
of granulocyte colony-stimulating factor for the treatments of severe 
endoscopic postoperative recurrence in Crohn’s disease. Digestion, 
68:63–70.
Dieckgraefe BK, Korzenik JR. 2002. Treatment of active Crohn’s disease 
with recombinant human granulocyte-macrophage colony-stimulating 
factor. Lancet, 260:1478–80.
Dieckgraefe BK, Korzenik JR, Anant S. 2006. Growth factors as treatment 
options for intestinal inﬂ  ammation. Ann N Y Acad Sci, 1072:300–6.
Elmgreen J. 1986. Complement and function of neutrophils in chronic 
inﬂ  ammatory bowel disease. Dan Med Bull, 33:222–28.
Fata F, Myers P, Addeo J, et al. 1997. Cyclic neutropenia in Crohn’s 
ileocolitis: efﬁ  cacy of granulocyte colony-stimulating factor. J Clin 
Gastroenterol, 24:253–6.
Fellermann K, Wehkamp J, Herrlinger KR, et al. Crohn’s disease: a defensin 
deﬁ  ciency syndrome? 2003. Eur J Gastrenterol Hepatol, 15:627–34.
Harbord MW, Marks DJ, Forbes A, et al. 2006. Impaired Neutrophil 
chemotaxis in Crohn’s disease relates to reduced production of chemo-
kines and can be augmented by granulocyte-colony stimulating factor. 
Aliment Pharmacol Ther, 24:651–60.
Hommes DW, Meenan J, Dijkhuizen S, et al. 1996. Efﬁ  cacy of recombi-
nant granulocyte colony-stimulating factor (rhG-CSF) in experimental 
colitis. Clin Exp Immunol, 106:529–33.
Kenji I, Kusugami K, Hosokawa T, et al. 1999. Increased mucosal produc-
tion of granulocyte colony-stimulating factor is related to a delay in 
neutrophil apoptosis in Inﬂ  ammatory Bowel Disease. J Gastroenterol 
Hepatol, 14:46–53.
Korzenik JR, Dieckgraefe BK, Valentine JF, et al. 2005. Sargramostim for 
Active Crohn’s Disease. N Engl J Med, 352:2193–201.
Korzenik JR, Dieckgraefe BK. 2005. An open-labelled study of granulocyte 
colony-stimulating factor in the treatment of active Crohn’s disease. 
Aliment Pharmacol Ther, 21:391–400.
Kramer M, Netea MG, de Jong DJ, et al. 2006. Impaired dendritic cell 
function in Crohn’s disease patients with NOD2 3020insC mutation. 
J Leukoc Biol, 79:860–66.
Marks DJ, Harbord MW, MacAllister R, et al. 2006. Defective acute 
inﬂ  ammation in Crohn’s disease: a clinical investigation. Lancet, 
367:668–78.
Marks DJ, Segal AW. Innate immunity in inﬂ  ammatory bowel disease: a 
disease hypothesis. 2008. J Pathol, 214:260–6.
Myrup B, Valerius NH, Mortensen PB. 1998. Treatment of enteritis in 
chronic granulomatous disease with granulocyte colony stimulating 
factor. Gut, 42:127–30.
Netea MG, Ferwerda G, de Jong DJ, et al. 2005. Nucleotide-Binding 
Oligomerization Domain-2 modulates speciﬁ  c TLR pathways for the 
induction of cytokine release. J Immunol, 174:6518–23.
Rahman FZ, Marks DJ, Hayee BH, et al. 2008. Phagocyte dysfunction 
and inﬂ  ammatory bowel disease. Inﬂ  amm Bowel Dis. DOI: 10.1002/
ibd.20449.
Roe TF, Coates TD, Thomas DW, et al. 1992. Brief report: treatment of 
chronic inﬂ  ammatory bowel disease in glycogen storage disease type 
Ib with colony-stimulating factors. N Engl J Med, 326:1666–9.
Sainathan SK, Hanna EM, Gong Q, et al. 2008. Granulocyte macrophage 
colony-stimulating factor ameliorates DSS-induced experimental 
colitis. Inﬂ  amm Bowel Dis, 14:88–99.
Segal AW, Loewi G. Neutrophil dysfunction in Crohn’s disease. 1976. 
Lancet, 2:219–21.
Simms LA, Doecke JD, Walsh MD, et al. 2008. Reduced alpha-defensin 
expression is associated with inﬂ  ammation and not NOD2 mutation 
status in ileal Crohn’s disease. Gut. DOI:10.1136/gut.2007.142588.
van Heel DA, Ghosh S, Butler M, et al. 2005. Muramyl dipeptide and toll-
like receptor sensitivity in NOD2-associated Crohn’s disease. Lancet, 
365:1794–6.
Wandall, J.H. 1985. Function of exudative neutrophilic granulocytes in 
patients with Crohn’s disease or ulcerative colitis. Scand J Gastroen-
terol, 20: 1151–6.
Wehkamp J, Harder J, Weichenthal M, et al. 2004. NOD2 (CARD15) 
mutations in Crohn’s disease are associated with diminished mucosal 
α-defensin expression. Gut, 53: 1658–64.
Yamamoto-Furusho JK, Korzenik JR. 2006. Crohn’s disease: Innate 
immunodeﬁ  ciency? World J Gastroenterol, 12:6751–5.
Yoshimitsu M, Hayamizu K, Egi H, et al. 2006. The neutrophil/Th1 
lymphocyte balance and the therapeutic effect of granulocyte colony-
stimulating factor in TNBS-induced colitis of rat strains. J Interferon 
Cytokine Res, 26:291–300.